352563-21-4
352563-21-4
Chemical Structure
Ogremorphin
Synonym(s): OGM; GPR68-IN-1; OGM-8345
- CAS No.: 352563-21-4
- Formula:C21H17N3OS
- Molecular Weight:359.44
InChIKey: FXTVKHHEAAQZHM-UHFFFAOYSA-N
SMILES: O=C1NC2=CC=C(CC)C=C2C13SC(C4=C5C=CC=CC5=CC=C4)=NN3
Biological Activity: Ogremorphin (OGM) is a G protein coupled sensor GPR68 inhibitor with anti-inflammatory and anti-tumor activities. Ogremorphin can inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells[1][2][3].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ogremorphin | 99.13% | Ogremorphin (OGM) is a G protein coupled sensor GPR68 inhibitor with anti-inflammatory and anti-tumor activities. Ogremorphin can inhibit the migration of human melanoma cells and induce ferroptosis in glioblastoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.78
HY-135710ADAMTS-5-IN-2 -
Similarity Score 0.65
HY-116788Lipofermata -
Similarity Score 0.56
HY-119331CFM-5 -
Similarity Score 0.56
HY-103255CFM-4 -
Similarity Score 0.55
HY-136861Antibacterial agent 192 -
Similarity Score 0.48
HY-124070ISA 27 -
Similarity Score 0.46
HY-143470SARS-CoV-2-IN-18 -
Similarity Score 0.46
HY-155187SARS-CoV-2 3CLpro-IN-20 -
Similarity Score 0.45
HY-116624MAZ51 -
Explore the MedChemAI to find more analogs
References
- [1]. Karki P, et al. A Novel Group of Ogremorphin Inhibitors Targeting G Protein-coupled Sensor GPR68 Rescue Lipopolysaccharide or Acidosis-induced Lung Endothelial Dysfunction[M]//C108. MECHANISMS OF LUNG INFLAMMATION AND INFECTION. American Thoracic Society, 2024: A6846-A6846.
- [2]. Williams C H, et al. Coupling Metastasis to pH-Sensing GPR68 Using a Novel Small Molecule Inhibitor[J]. BioRxiv, 2019: 612549.
- [3]. Williams C H, et al. GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment. Exp Hematol Oncol. 2024 Jan 31;13(1):13. [Content Brief]
